We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible

By LabMedica International staff writers
Posted on 01 Dec 2023

Home testing gained significant importance during the COVID-19 pandemic, yet the availability of rapid tests is limited, and most of them can only drive one liquid across the strip, leading to continued reliance on centralized laboratory diagnostics. More...

Now, a significant advancement has been achieved in diagnostic technology with the development of a 'lab on a chip' that can be created through 3D printing in just half an hour. This innovation holds the potential to make rapid, on-site testing widely accessible.

As part of a recent study, researchers at McGill University (Montreal, QC, Canada) have pioneered the development of capillaric chips, which essentially serve as miniaturized laboratories. In contrast to other computer microprocessors, these chips are designed for single use and do not need an external power source; they operate efficiently using just a paper strip. Their functionality is based on capillary action, the natural process that enables liquid to spontaneously move into an absorbent material, like a paper towel absorbing a spill on a table. Remarkably, these chips can be tailored through 3D printing for a variety of tests, including the quantification of COVID-19 antibodies.

This advancement brings the concept of 3D-printed home diagnostics closer to practical application, though challenges like obtaining regulatory approvals and securing the necessary testing materials still exist. The research team is committed to enhancing the accessibility of this technology, focusing on adapting it for use with more affordable 3D printers. innovation aims to accelerate diagnostic processes, improve patient care, and usher in a new era of convenient and accessible testing options.

“Traditional diagnostics require peripherals, while ours can circumvent them. Our diagnostics are a bit what the cell phone was to traditional desktop computers that required a separate monitor, keyboard and power supply to operate,” explained Prof. David Juncker, Chair of the Department of Biomedical Engineering at McGill and senior author on the study. “This advancement has the capacity to empower individuals, researchers, and industries to explore new possibilities and applications in a more cost-effective and user-friendly manner. This innovation also holds the potential to eventually empower health professionals with the ability to rapidly create tailored solutions for specific needs right at the point-of-care.”

Related Links:
McGill University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.